Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has announced a breakthrough in treating depressive disorders with their proprietary psychedelic microdosing treatment, MB22001, showing significant improvements in sleep quality and duration. Published research in the Translational Psychiatry journal indicates that MB22001 not only enhances mood and energy but also extends sleep by an average of 24 minutes, with an additional 8 minutes of REM sleep. This innovative treatment aims to revolutionize mental health care by providing an effective alternative to traditional antidepressants, targeting both depression and the related sleep disturbances.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
